This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jan V. Hirschmann, MD; Benjamin A. Lipsky, MD

Arch Intern Med. 1994;154(4):373-380.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN LATE 1977, the Food and Drug-Administration (FDA) licensed a pneumococcal vaccine containing antigens from 14 of the 83 known serotypes of Streptococcus pneumoniae, and in 1983 the manufacturers expanded the preparation to 23 antigens. Eversince the vaccine's release, many groups, including the Immunization Practice Advisory Committee sponsored by the US Public Health Service, have endorsed a nationwide vaccination program for people with increased susceptibility to pneumococcal disease. The most recent statement of the Immunization Practices Advisory Committee,¹ issued in 1989, recommends immunizing (1) everyone aged 65 years or older; (2) all individuals 2 years of age or older with chronic illnesses (such as diabetes mellitus, alcoholism, cirrhosis, cerebrospinal fluid leaks, unspecified cardiovascular and pulmonary diseases), immunocompromising disorders (such as anatomic or functional asplenia, nephrotic syndrome, chronic renal failure, lymphoma, multiple myeloma, organ transplantation), or human immunodeficiency virus infection; and (3) persons living in special environments or social settings . . . [Full Text PDF of this Article]

Author Affiliations
Medical Service (111) Seattle Veterans Affairs Medical Center 1660 S Columbian Way Seattle, WA 98108

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?